Biotech Funding Roundup: March 23-27, 2026

Biotech Funding Roundup: March 2026

The past week in biotech has been defined by a confluence of strategic capital deployment and heightened geopolitical tension. While investors continue to place significant bets on next-generation platforms like oral peptides, AI-driven therapies, and novel delivery systems, senior U.S. officials are framing the global biotech competition in starkly adversarial terms. Against this backdrop, funding activity remains robust, targeting both cutting-edge science and proven commercial pathways, even as regulatory and competitive pressures intensify.

Notable Rounds

This period saw several substantial private financings, with capital flowing into diverse areas from neuroscience to drug delivery. The following table summarizes the key funding rounds announced:

Company	Amount Raised	Focus Area	Key Detail
Pinnacle Medicines	$89 Million	Oral Peptides	Backed by U.S. and China investors 10.
Gilgamesh Pharma	$60 Million	Neuroscience/Psychedelics	Funding follows an AbbVie partnership 12.
Vaxess Technologies	$50 Million	Drug Delivery	Pivoting from microneedle vaccine patches to GLP-1 delivery 19.

Pinnacle Medicines secured one of the largest rounds, pulling in $89 million from a syndicate of investors in both the United States and China 10. The two-year-old startup is focused on developing oral peptide medicines, a field galvanized by the clinical success of pill versions of drugs like Novo Nordisk's Wegovy.

In neuroscience, Gilgamesh Pharma raised $60 million to advance its pipeline of psychedelics and other experimental neuroscience medicines 12. This financing is notable as it supports programs the New York City-based biotech has not yet partnered away, following a prior deal with AbbVie.

Vaxess Technologies, a company originally launched to commercialize microneedle patches for vaccines, has successfully pivoted and raised $50 million to apply its delivery technology to the lucrative GLP-1 market 19. The round underscores investor appetite for novel delivery mechanisms that could improve convenience and adherence for blockbuster drug classes.

Deal Activity

Mergers and acquisitions presented a major storyline, headlined by a multi-billion dollar buyout offer and a strategic oncology acquisition.

Merck moved to bolster its oncology portfolio with a $6.7 billion cash acquisition of Terns Pharmaceuticals 22. The deal gives Merck control of Terns' investigational treatment for chronic myeloid leukemia, a drug viewed as a potential challenger to Novartis's Scemblix.

In Europe, private equity showed its continued interest in the sector. Milan-based Recordati confirmed it has received a takeover bid exceeding $12 billion from the private equity firm CVC Capital Partners 3.

Beyond M&A, partnership and strategic activity continued. Boehringer Ingelheim indicated that its strategic approach includes active dealmaking and could involve looking at China-based companies for partnerships 17. Furthermore, UCB announced a major $2 billion investment to build a new 460,000-square-foot biologics manufacturing site in Gwinnett County, Georgia, to supply the U.S. market 4.

Market Context

The funding and deal activity occurs within a complex and sometimes contentious market environment. A senior HHS official and head of Medicare, Chris Klomp, recently described competition with China’s ascending biotech industry as “a war,” highlighting the geopolitical stakes now attached to biotech leadership 1. Concurrently, the industry is pushing back on certain FDA proposals in the new user fee negotiations, particularly those that would limit small business waivers to U.S. applicants, which some view as overly political "America First" policies 2.

Regulatory outcomes have been mixed, providing both tailwinds and headwinds. Denali Therapeutics received an accelerated approval for its rare disease drug Avlayah (tividenofusp), a decision that bucks a recent trend of rejections in the space 21. Corcept Therapeutics also saw an early FDA approval for Lifyorli in ovarian cancer 14. However, not all news was positive, as demonstrated by Wave Life Sciences, whose non-GLP-1 obesity candidate disappointed, underscoring the high clinical bar in that market 6.

On the clinical front, promising updates are fueling future investment narratives. Beam Therapeutics is now looking toward an accelerated approval pathway for its base editing therapy for alpha-1 antitrypsin deficiency (AATD) after a promising data update 16. Maze Therapeutics reported positive Phase 2 data for its kidney disease drug MZE829, positioning it as a potential competitor to a Vertex Pharmaceuticals program 20. Kodiak also reported a Phase 3 success for its eye drug Zenkuda (tarcocimab tedromer) 7.

What This Means

The past week's activity reveals a biotech sector navigating multiple fronts. Capital remains available for high-conviction stories, particularly those leveraging platform technologies (oral peptides, AI, novel delivery) or addressing clear commercial opportunities (oncology, GLP-1s). The significant M&A, from Merck's strategic buy to the large PE bid for Recordati, indicates continued appetite for assets that can bolster pipelines or portfolios.

However, this financial activity is increasingly set against a backdrop of strategic national competition and regulatory evolution. The stark rhetoric from U.S. officials regarding China, combined with policy debates over FDA user fees, signals that biotech is firmly in the crosshairs of geopolitical and domestic policy agendas. Companies and investors must now account for these broader forces, which could influence everything from partnership strategies to market access, even as they pursue scientific and clinical milestones. The sector's resilience is being tested not just in the clinic, but in the global arena.

---